Patients and Methods
Abbreviations and Acronyms:AB (alpha-adrenergic blocker), BPH (benign prostatic hyperplasia), 5-ARI (5-alpha reductase inhibitor), LUTS (lower urinary tract symptom), PCPT (Prostate Cancer Prevention Trial), PSA (prostate specific antigen), SHR (subdistribution hazard ratio)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Mayo Clinic Proceedings
- The influence of finasteride on the development of prostate cancer.N Engl J Med. 2003; 349: 215-224
- Effect of dutasteride on the risk of prostate cancer.N Engl J Med. 2010; 362: 1192-1202
- Prevention of prostate cancer with finasteride.N Engl J Med. 2003; 349: 1569-1572
- The prevention of prostate cancer — the dilemma continues.N Engl J Med. 2003; 349: 297-299
- A big study yields big questions.N Engl J Med. 2003; 349: 213-214
- Effect of 5α-reductase inhibitor use on mortality from prostate cancer.JAMA Oncol. 2015; 1: 321-322
- A role for finasteride in the prevention of prostate cancer?.N Engl J Med. 2013; 369: 670-671
- 5A-reductase inhibitors and the risk of cancer-related mortality in men with prostate cancer.JAMA Oncol. 2015; 1: 314-320
- 5alpha-Reductase inhibitors and risk of high-grade or lethal prostate cancer.JAMA Intern Med. 2014; 174: 1301-1307
- Long-term survival of participants in the prostate cancer prevention trial.N Engl J Med. 2013; 369: 603-610
- Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.Perm J. 2012; 16: 37-41
- The HMO Research Network Virtual Data Warehouse: a public data model to support collaboration.EGEMS (Wash DC). 2014; 2: 1049
- A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.J Chronic Dis. 1987; 40: 373-383
- A proportional hazards model for the subdistribution of a competing risk.J Am Stat Assoc. 1999; 94: 496-509
- Proportional hazards tests and diagnostics based on weighted residuals.Biometrika. 1994; 81: 515-526
- 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.Int J Cancer. 2016; 138: 2820-2828
FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. http://www.fda.gov/Drugs/DrugSafety/ucm258314.htm. Accessed June 30, 2015.
- High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact?.J Natl Cancer Inst. 2007; 99: 1355-1356
- The prostate cancer prevention trial: design, biases and interpretation of study results.J Urol. 2006; 175: 2234-2242
- Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.Cancer Prev Res (Phila). 2008; 1: 174-181
- Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.Cancer Prev Res (Phila). 2008; 1: 167-173
- Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.J Natl Cancer Inst. 2006; 98: 1128-1133
- Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.J Natl Cancer Inst. 2007; 99: 1366-1374
- Immortal time bias in observational studies of drug effects.Pharmacoepidemiol Drug Saf. 2007; 16: 241-249
Grant Support: The work was supported by a research grant (no. 116059) from GlaxoSmithKline. Although the sponsor had an opportunity to comment on the manuscript, it did not have access to the data and all analyses were conducted at Kaiser Permanente Southern California. Drs Wallner and Jacobsen had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Dr Wallner made the final decision to submit this manuscript for publication and was not paid by any other organization or agency to write this article.
Potential Competing Interests: Drs Wallner, DiBello, Van Den Eeden, Abell, Jacobsen, D'Agsotino Jr, Loo, and Horwitz report funding from GlaxoSmithKline for this study. Dr Van Den Eeden report funding from Takeda not related to the topic of this study. Drs Li, Weinmann, Ritzwoller, Aaronson, and Richert-Boe have no additional financial disclosures to report.